Brain metastases in patients with EGFR -mutated or ALK - rearranged non-small-cell lung cancers
|
|
- Lora Chandler
- 5 years ago
- Views:
Transcription
1 Brain metastases in patients with EGFR -mutated or ALK - rearranged non-small-cell lung cancers The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published Version Accessed Citable Link Terms of Use Rangachari, Deepa, Norihiro Yamaguchi, Paul A. VanderLaan, Erik Folch, Anand Mahadevan, Scott R. Floyd, Erik J. Uhlmann, et al Brain Metastases in Patients with EGFR -Mutated or ALK -Rearranged Non-Small-Cell Lung Cancers. Lung Cancer 88 (1) (April): doi: /j.lungcan doi: /j.lungcan August 21, :56:31 PM EDT This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at (Article begins on next page)
2 Brain metastases in patients with EGFR-mutated or ALKrearranged non-small-cell lung cancers Deepa Rangachari, MD 1, Norihiro Yamaguchi, MD, MPH 1, Paul A. VanderLaan, MD, PhD 2, Erik Folch, MD, MSc 1,3, Anand Mahadevan, MD 4, Scott R. Floyd, MD, PhD 4, Erik J. Uhlmann, MD 5, Eric T. Wong, MD 5, Suzanne E. Dahlberg, PhD 6, Mark S. Huberman, MD 1, and Daniel B. Costa, MD, PhD 1,* 1 Department of Medicine, Harvard Medical School, Boston, MA 2 Department of Pathology, Harvard Medical School, Boston, MA 3 Department of Surgery, Harvard Medical School, Boston, MA 4 Department of Radiation Oncology, Harvard Medical School, Boston, MA 5 Department of Neurology; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 6 Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Health, Harvard Medical School, Boston, MA Abstract HHS Public Access Author manuscript Published in final edited form as: Lung Cancer April ; 88(1): doi: /j.lungcan Introduction Brain metastases (BM) are common in non-small-cell lung cancer (NSCLC). However, the baseline incidence and evolution of BM over time in oncogene-driven NSCLCs are seldom reported. In this study, we evaluated the frequency of BM in patients with epidermal growth factor receptor (EGFR)-mutated or anaplastic lymphoma kinase (ALK)-rearranged NSCLC. Methods The presence of BM, clinicopathologic data, and tumor genotype were retrospectively compiled and analyzed from a cohort of 381 patients. Results We identified 86 EGFR-mutated (90.7% with metastatic disease; 85.9% received an EGFR inhibitor) and 23 ALK-rearranged (91.3% with metastatic disease; 85.7% received an ALK inhibitor) NSCLCs. BM were present in 24.4% of EGFR-mutated and 23.8% of ALK-rearranged NSCLCs at the time of diagnosis of advanced disease. This study did not demonstrate a difference in the cumulative incidence of BM over time between the two cohorts (EGFR/ALK cohort 2015 Published by Elsevier Ltd. This manuscript version is made available under the CC BY-NC-ND 4.0 license. Corresponding Author: Daniel B. Costa, MD, PhD, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215, Phone: , Fax: , dbcosta@bidmc.harvard.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Conflict of interest: annexed separately.
3 Rangachari et al. Page 2 competing risk regression [CRR] coefficient of 0.78 [95% CI ], p=0.41). In still living patients with advanced EGFR-mutated NSCLC, 34.2% had BM at 1 year, 38.4% at 2 years, 46.7% at 3 years, 48.7% at 4 years, and 52.9% at 5 years. In still living patients with advanced ALKrearranged NSCLC, 23.8% had BM at 1 year, 45.5% at 2 years, and 58.4% at 3 years. Conclusions BM are frequent in advanced EGFR-mutated or ALK-rearranged NSCLCs, with an estimated >45% of patients with CNS involvement by three years of survival with the use of targeted therapies. These data point toward the CNS as an important unmet clinical need in the evolving schema for personalized care in NSCLC. Keywords lung cancer; NSCLC; brain metastases; EGFR; ALK; mutation; rearrangement; central nervous system; CNS INTRODUCTION Non-small-cell lung cancer (NSCLC) is the leading cause of brain metastases (BM) (1). Amongst those with recurrent/advanced NSCLC, BM are a common culprit for cancerrelated morbidity and mortality. The incidence of BM in NSCLC has been reported as >20% at diagnosis, with a significant proportion of patients developing BM over the course of their disease (2, 3). Recent reports also demonstrate an increase in the documented incidence of BM in NSCLC, likely as a consequence of prolonged survival with newer therapies coupled with improvements in neuroimaging modalities (4). Far less is known about the baseline incidence and subsequent evolution of BM in the subset of patients with oncogene-driven tumors, i.e. epidermal growth factor (EGFR)-mutated or anaplastic lymphoma kinase (ALK)-rearranged NSCLC (5, 6). Given the growing emphasis on molecular profiling and use of targeted therapeutics (7), this is a critical population. An improved understanding of the incidence and evolution of BM in these cases is therefore an area of ongoing need. Herein, we report the baseline and cumulative incidence of BM in patients with EGFRmutated or ALK-rearranged advanced NSCLC. MATERIALS AND METHODS Cohort selection Tumor genotype Patients seen at Beth Israel Deaconess Medical Center (BIDMC) with a diagnosis of NSCLC and whose tumors were genotyped were identified through an ongoing Institutional Review Board-approved study (8,9), with a data cutoff of December 19, 2012 for patient inclusion and June 24, 2014 for outcomes. EGFR mutation analysis (exons 18 to 21) was performed using standard sequencing techniques, and ALK rearrangement was analyzed using the Vysis ALK break-apart fluorescence in situ hybridization (FISH) probe (8).
4 Rangachari et al. Page 3 Data collection and detection of BM Statistical methods RESULTS Data was collected by retrospective chart review and managed using REDCap electronic data capture tools hosted at BIDMC. All patients with advanced NSCLC (stage IV/recurrent disease) had baseline CNS evaluation with either computed tomography (CT) or magnetic resonance imaging (MRI). Subsequent CNS assessment was performed at the discretion of the treating physicians. BM were diagnosed either radiographically or pathologically (tumor resection/biopsy or malignant CSF cytology). Fisher s exact test was used to compare categorical variables, and Wilcoxon rank test was used for continuous variables. All p-values reported are two-sided, and tests were conducted at the 0.05-level. Time to BM was defined as the time from diagnosis to date of detected BM, and cumulative incidence curves were fitted and compared using the methodologies of Fine and Gray (10), adjusting for death as a competing risk. Patients not experiencing BM or death by the time of data cutoff were censored at their last date of follow-up. Overall survival (OS) was analyzed using the Kaplan Meier method. Statistical analyses and curves were performed with the cmprsk package in R Statistical Programming Language. Patient and tumor characteristics The complete cohort comprised 381 patients, with a median age at diagnosis of 65 years. Self-reported racial groups were 75.9% white, 13.1% Asian, 6.5% black, and 4.4% other. 27.8% of patients were never smokers, 54.9% were former smokers, and 17.3% current smokers. At the time of initial entry into the cohort, 73.8% had stage IV/recurrent disease, and 86.1% had adenocarcinoma histology. EGFR and ALK analysis was successful in 94.2% (359/381) and 91.6% (252/275) of tested samples, respectively (8). The overall frequency of EGFR mutations and ALK FISH positivity was 23.9% (86/359) and 9.1% (23/252), respectively. Abnormalities in EGFR and ALK were mutually exclusive in all genotyped tumors. Characteristics of EGFR-mutated or ALK-rearranged NSCLCs The EGFR-mutated cohort was comprised of more women; however, both cohorts predominantly involved patients with no tobacco history, advanced disease, and adenocarcinoma histology (Table 1). 85.9% (67/86) of patients with EGFR-mutated NSCLCs received an EGFR tyrosine kinase inhibitor (TKI) -gefitinib, erlotinib, or dacomitinib at some point in their treatment course. 85.7% (18/23) of patients with ALKrearranged NSCLCs received the ALK TKI, crizotinib (Table 1). The median follow-up for patients with EGFR-mutated and ALK-rearranged NSCLC was 45.2 and 36.4 months, respectively.
5 Rangachari et al. Page 4 BM in EGFR-mutated NSCLC 24.4% (19/78) of the patients with EGFR-mutated NSCLC had BM at initial evaluation. The cumulative incidence of post-diagnosis BM increased over time (Figure 1A): 34.2% at 1 year, 38.4% at 2 years, 46.7% at 3 years, 48.7% at 4 years, and 52.9% at 5 years. BM in ALK-rearranged NSCLC 23.8% (5/21) of the patients with ALK-rearranged NSCLC had BM at initial evaluation. The cumulative incidence of post-diagnosis BM increased over time (Figure 1A): 23.8% at 1 year, 45.5% at 2 years, and 58.4% at 3 years. At the time of data cutoff, none of the patients with ALK-rearranged NSCLC had reached beyond the 4-year survival mark. Differences in BM between EGFR-mutated and ALK-rearranged NSCLC Overall survival DISCUSSION No statistically significant difference was observed in the baseline and subsequent incidence of BM with EGFR-mutated versus ALK-rearranged tumors (Figure 1A). Additionally, this study did not demonstrate a difference in the cumulative incidence of BM over time between the two cohorts (EGFR/ALK cohort CRR coefficient of 0.78 [95% CI ], p=0.41). However, since the ALK-rearranged cohort had fewer patients and less follow-up time than the EGFR-mutated group, it is unknown if differences may have evolved during subsequent follow-up. Survival curves are depicted in Figure 1B. Amongst the 78 patients with an EGFR mutation, the median OS was 34.4 months (95% CI ). Median OS amongst the 21 patients with an ALK rearrangement was 38.3 months (95% CI 22.3-NA). We retrospectively evaluated a cohort of patients with EGFR-mutated or ALK-rearranged advanced NSCLC. BM were common, with nearly 25% of patients with BM at initial diagnosis and approximately half of patients with BM by 3 years in the setting of precision therapies. Limitations of this study include its retrospective nature and the lack of a standardized protocol for CNS assessment. Nevertheless, to our knowledge, this is the largest study to assess the baseline incidence and subsequent evolution of BM in these molecularly-defined groups. The clinical course of patients with these oncogene-driven NSCLCs is an area of ongoing investigation. The University of Colorado evaluated patterns of metastatic spread in 209 patients with treatment-naïve EGFR-mutated, KRAS-mutated, ALK-rearranged, and EGFR/ KRAS/ALK-unaffected advanced NSCLC (11). Similar to our findings, BM was present at diagnosis in 23% and 24% of EGFR-mutated and ALK-rearranged patients, respectively (11). In one retrospective study, BM were reported in 8% (5 of 62) EGFR-mutated patients at diagnosis, with an additional 24% diagnosed with BM at follow-up (12). The overall incidence of BM in this cohort was 32%, and time to BM and post-bm survival were 20.8 and 12.1 months, respectively (12). One other study of 93 patients with NSCLC and BM undergoing mutational analysis for EGFR found 49% (20 of 41) of EGFR-mutated NSCLCs
6 Rangachari et al. Page 5 with synchronous BM at the time of initial diagnosis (13). Time to progression in the brain was non-significantly longer in EGFR-mutated NSCLCs as compared to those with wildtype EGFR (13). The prevalence of BM in the published trials of TKIs in advanced NSCLC to-date is similarly impressive, with more than 10% of patients in the first line trials of EGFR TKIs (5) and 35% of patients in the second line trials of ALK TKIs (6) noted to have baseline asymptomatic BM. As targeted therapies continue to improve outcomes for patients with molecularly-driven NSCLCs (5 7), the deterrence of BM has become an increasingly relevant therapeutic dilemma. Most available TKIs (gefitinib, erlotinib, and crizotinib) inefficiently cross the intact blood brain barrier with cerebrospinal fluid-to-plasma ratios as low as 0.01 to detected in patients (14). Even so, it seems that their use can still alter the natural history of BM. In one report of 155 EGFR-mutated NSCLCs, the 12- and 24-month cumulative risk of CNS progression was 6% and 21% in the group initially treated with an EGFR TKI, as compared to 19% and 32% in the group receiving first line chemotherapy; a hazard ratio of 0.56 (95% CI ) was noted for CNS progression, favoring upfront EGFR TKI over chemotherapy (15). Although a similar comparison has not been performed for ALKrearranged NSCLC, crizotinib and other ALK TKIs (such as ceritinib and alectinib) can also positively influence CNS disease (7). Ceritinib and alectinib have reported CNS activity in patients with ALK-rearranged NSCLC that are naïve or resistant to crizotinib therapy (7). Since our group s cohort and those of others (5 7) predominantly studied patients that received TKIs, it is tempting to postulate that the cumulative incidence of BM may have been even higher in patients treated with chemotherapy alone. Contemporary clinical trials of novel EGFR and ALK TKIs now mandate baseline CNS imaging at study entry for all patients and have started to stratify patients based on presence/absence of BM. Such efforts will hopefully define prospectively whether CNS and systemic sites differ in patterns of response/progression in the setting of TKI use (7). Moreover, these studies will aid in delineating strategies for optimal surveillance for and detection of BM early in the course of CNS progression, for which there is currently no established standard. Acquired resistance to targeted therapies remains a key limitation in achieving a durable benefit. Even as the major mechanisms of acquired systemic resistance are known to result from resistant tyrosine kinase mutations and activation of bypass pathways (7), the mechanisms that explain CNS progression remain largely unknown. As reported here and elsewhere (5 7, 10 12), the CNS is amongst the most frequent sites of disease progression in patients whose systemic disease is otherwise being successfully controlled with TKIs. The optimal management of BM in oncogene-driven NSCLCs remains uncertain, and the use of whole brain or stereotactic radiotherapy remains a cornerstone of care (16). In conclusion, this retrospective study demonstrates the high initial incidence (nearly 25%) and subsequent prevalence of BM in patients with advanced EGFR-mutated or ALKrearranged NSCLCs treated with TKIs. Given their frequency in tumors with these driver mutations, increased inclusion of patients with BM in innovative trials of targeted therapies will be critical in defining their full potential and facilitating their application in real-world practice. Developing optimal strategies for the prevention and management of CNS disease has become one of the foremost clinical questions in the care of these patients. Future
7 Rangachari et al. Page 6 Acknowledgments References studies should address the role of TKIs with improved CNS penetration, the use of less toxic radiotherapy techniques for BM, and the need to better understand the molecular underpinnings of malignant CNS disease. This work was funded in part through a fellowship from the American Society of Clinical Oncology Conquer Cancer Foundation (DBC), an American Cancer Society grant (RSG to DBC), a Lung Cancer Foundation of America-International Association for the Study of Lung Cancer grant (to DBC), National Institutes of Health (NIH) grant CA (to DBC), and Gallup Funds from the Thoracic Oncology Program at the Dana-Farber Cancer Institute (to SED). 1. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012; 14: [PubMed: ] 2. Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB, Aquino SL. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol. 2006; 1: [PubMed: ] 3. Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010; 16: [PubMed: ] 4. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004; 22: [PubMed: ] 5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: [PubMed: ] 6. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: [PubMed: ] 7. Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book. 2014:e353 e365. [PubMed: ] 8. VanderLaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, et al. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-smallcell lung cancer. Lung Cancer. 2014; 84: [PubMed: ] 9. Yamaguchi N, VanderLaan PA, Folch E, Boucher DH, Canepa HM, Kent MS, et al. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-smallcell lung cancers at a United States-based academic medical practice. Lung Cancer. 2013; 82:31 7. [PubMed: ] 10. Fine JP, Grayzel D. A Proportional Hazards Model for the Subdistribution of a Competing Risk. Journal of the American Statistical Association. 1999; 94: Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012; 118: [PubMed: ] 12. Hendriks LE, Smit EF, Vosse BA, Mellema WW, Heideman DA, Bootsma GP, et al. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases? Lung Cancer. 2014; 84: [PubMed: ] 13. Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010; 12: [PubMed: ]
8 Rangachari et al. Page Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011; 29:e443 e445. [PubMed: ] 15. Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced nonsmall cell lung cancer with EGFR mutations. Clin Cancer Res. 2012; 18: [PubMed: ] 16. Zimmermann S, Dziadziuszko R, Peters S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev. 2014; 40: [PubMed: ]
9 Rangachari et al. Page 8 HIGHLIGHTS - Brain metastases are frequent in ALK rearranged lung cancers - Brain metastases are frequent in EGFR mutated lung cancers - ~25% of patients at diagnosis and half at 3-years of survival have brain metastases
10 Rangachari et al. Page 9 Figure 1.
11 Rangachari et al. Page 10 Table 1 Baseline characteristics of patients and tumors with EGFR-mutated and ALK-rearranged NSCLC. Age at time of biopsy EGFR-mutated (n=86) Tumor genotype ALK-rearranged (n=23) p-value Median (range) 65 (33 90) 56 (29 80) < * Women n (%) 64 (74.4) 11 (47.8) Race n (%) White 50 (58.1) 15 (65.2) Asian 31 (36.1) 4 (17.4) Black 4 (4.6) 0 (0) Other 1 (1.2) 4 (17.4) Smoking status n (%) Current smoker 4 (4.65) 1 (4.3) Former smoker 37 (43.0) 8 (34.8) Never smoker 45 (52.3) 14 (60.9) Stage n (%) I III 8 (9.3) 2 (8.7) IV/recurrent 78 (90.7) 21 (91.3) Histology n (%) Adenocarcinoma 84 (97.7) 21 (91.3) Squamous cell carcinoma 0 (0) 1 (4.3) NSCLC (NOS) 2 (2.3) 1 (4.3) Use of precision TKI n (%) When stage IV/recurrent 67 (85.9) 18 (85.7) Baseline brain metastases n (%) When stage IV/recurrent 19 (24.4) 5 (23.8) NSCLC = non-small-cell lung cancer; NOS = not otherwise specified; TKI = tyrosine kinase inhibitor. * Wilcoxon-Rank Sum test
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
Hidetoshi Hayashi, Kazuhiko Nakagawa
Editorial Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation
Improving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases
Original Article Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases Yuan-Yuan Lei 1,2, Jin-Ji Yang 2, Wen-Zhao Zhong 2, Hua-Jun Chen
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
D Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
Molecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
RESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with nonsmall cell lung cancer
ORIGINAL ARTICLE Korean J Intern Med 218;33:168-175 https://doi.org/1.394/kjim.215.158 Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with nonsmall cell lung cancer
HHS Public Access Author manuscript Eur J Radiol. Author manuscript; available in PMC 2018 March 01.
Co-clinical quantitative tumor volume imaging in ALKrearranged NSCLC treated with crizotinib Mizuki Nishino, M.D., M.P.H. 1,2, Adrian G. Sacher, M.D. 3, Leena Gandhi, M.D. Ph.D. 3, Zhao Chen, PhD 3, Esra
Joachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
Lung cancer is ranked as the most common cause of cancer
BRIEF REPORT Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors Susumu Kobayashi, MD, PhD, Hannah M. Canepa, BA, Alexandra S. Bailey, MD, Sohei Nakayama, MD, PhD, Norihiro Yamaguchi,
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Recurrent response to advanced lung adenocarcinoma with erlotinib developing leptomeningeal metastases during gefitinib therapy and two case reports Puyuan
Brain metastases and meningitis carcinomatosa: Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland
Brain metastases and meningitis carcinomatosa: a palliative situation? Prof. Rafal Dziadziuszko Medical University of Gdańsk, Poland SAMO, Lucerne, February 1-2, 2013 Treatment options for NSCLC patients
Corporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
Practice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
Intracranial efficacy of crizotinib versus chemotherapy in PROFILE 1014: shining a light on central nervous system endpoints in clinical trials
Perspective Intracranial efficacy of crizotinib versus chemotherapy in PROFILE 1014: shining a light on central nervous system endpoints in clinical trials Terry L. Ng, D. Ross Camidge Division of Medical
Lung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
Personalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
DM Seminar. ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat
DM Seminar ALK gene rearrangements & ALK targeted therapy in NSCLC Dr Sarat Introduction Discovery of activating mutations in kinase domain of epidermal growth factor receptor (EGFR) opened a new era of
Rearrangement of the anaplastic lymphoma kinase (ALK)
Brief Report Clinical Implications of Variant ALK FISH Rearrangement Patterns Xin Gao, MD,* Lynette M. Sholl, MD,* Mizuki Nishino, MD,* Jennifer C. Heng, BS, Pasi A. Jänne, MD, PhD,* and Geoffrey R. Oxnard,
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non Small-Cell Lung Cancer and Brain Metastases
VOLUME 33 NUMBER 17 JUNE 1 215 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non Small-Cell Lung Cancer and Brain
Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer
Editorial ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer Viola W. Zhu 1,2, Sai-Hong Ignatius Ou 1 1 Division of Hematology/Oncology,
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
Original Article. Cancer January 1,
Twice Weekly Pulse and Daily Continuous-Dose Erlotinib as Initial Treatment for Patients With Epidermal Growth Factor Receptor Mutant Lung Cancers and Brain Metastases Kathryn C. Arbour, MD 1 ; Mark G.
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
Supplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma Hong
Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront?
The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront? Jeffrey Zweig, MD, and Heather Wakelee, MD Abstract Therapeutic options for advanced anaplastic lymphoma
GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
EGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
A large, single- center, real- world study of clinicopathological characteristics and treatment in advanced ALK- positive non- small- cell lung cancer
Cancer Medicine ORIGINAL RESEARCH Open Access A large, single- center, real- world study of clinicopathological characteristics and treatment in advanced ALK- positive non- small- cell lung cancer Gang
NCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
ALK positive Lung Cancer. Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan
ALK positive Lung Cancer Shirish M. Gadgeel, MD. Director of the Thoracic Oncology program University of Michigan Objectives What is ALK translocation? What drugs are used in what sequence? How many times
Research Article The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
Chemotherapy Research and Practice, Article ID 856156, 4 pages http://dx.doi.org/10.1155/2014/856156 Research Article The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients Vanita
Changing demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.
Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival The Harvard community has made this article openly
Test Category: Prognostic and Predictive. Clinical Scenario
Use of Epidermal Growth Factor Receptor (EGFR) Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) to Determine Erlotinib Use as First-line Therapy Test Category: Prognostic
ALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists
Accepted Manuscript Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists Shearwood McClelland, III, MD, Kiri
Correspondence should be addressed to Kumar Prabhash;
Hindawi Chemotherapy Research and Practice Volume 2017, Article ID 8196434, 4 pages https://doi.org/10.1155/2017/8196434 Clinical Study Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating
LUNG CANCER IN FOCUS. ALK Inhibitors in Non Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced?
LUNG CANCER IN FOCUS Current Developments in the Management of Section Editor: Mark A. Socinski, MD ALK Inhibitors in Non Small Cell : How Many Are Needed and How Should They Be Sequenced? Alice T. Shaw,
Title: Lung cancer (non-small-cell, anaplastic lymphoma kinase positive, previously treated) ceritinib
Title: Lung cancer (non-small-cell, anaplastic lymphoma kinase positive, previously treated) ceritinib Produced by ERG: Warwick Evidence Authors: Joshua Pink, Assistant Professor in Health Economics, Warwick
RECIST 1.1 in NSCLC Patients With EGFR Mutations Treated With EGFR Tyrosine Kinase Inhibitors: Comparison With RECIST 1.0
Cardiopulmonary Imaging Original Research Nishino et al. Comparison of RECIST 1.1 With 1. Cardiopulmonary Imaging Original Research Mizuki Nishino 1,2 Stephanie Cardarella 3 David M. Jackman 3 Nikhil H.
EGFR MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS IN SOUTH AFRICA
EGFR MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS IN SOUTH AFRICA Sze Wai Chan A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in partial
When Policy Topic is covered Crizotinib may be considered medically necessary in patients 18 years or older when the following criteria are met:
Xalkori (crizotinib) Policy Number: 5.01.539 Last Review: 6/2018 Origination: 7/2012 Next Review: 6/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for crizotinib
T he utility of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in metastatic nonsmall
OPEN SUBJECT AREAS: NON-SMALL-CELL LUNG CANCER TARGETED THERAPIES Received 30 April 2014 Accepted 15 July 2014 Published 8 August 2014 Correspondence and requests for materials should be addressed to H.L.
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
Published OnlineFirst June 25, 2012; DOI: / CCR
Cancer Therapy: Clinical Clinical Cancer Research The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non Small Cell Lung Cancer with EGFR
Page: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
Targeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
Lihong Ma 1 *, Zhengbo Song 2 *, Yong Song 1, Yiping Zhang 2. Original Article
Original Article MET overexpression coexisting with epidermal growth factor receptor mutation influence clinical efficacy of EGFR-tyrosine kinase inhibitors in lung adenocarcinoma patients Lihong Ma 1
Osimertinib: a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma
Editorial : a breakthrough for the treatment of epidermal growth factor receptor mutant lung adenocarcinoma Niki Karachaliou 1, Feliciano Barron Barron 2, Santiago Viteri 3, Miguel Angel Molina 4, Rafael
Recent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
Molecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
Accepted Manuscript. Keeping Surgery Relevant in Oligometastatic Non-Small Cell Lung Cancer. Jessica S. Donington, MD, MSCR
Accepted Manuscript Keeping Surgery Relevant in Oligometastatic Non-Small Cell Lung Cancer Jessica S. Donington, MD, MSCR PII: S0022-5223(18)32903-9 DOI: https://doi.org/10.1016/j.jtcvs.2018.10.124 Reference:
AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?
Editorial Page 1 of 5 AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC? Terry L. Ng, D. Ross Camidge Division of Medical Oncology, Department of Medicine, University of Colorado
Optimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
Personalized Medicine in Oncology and the Implication for Clinical Development
THE POWER OFx Experts. Experienc e. Execution. Personalized Medicine in Oncology and the Implication for Clinical Development Jamal Gasmi MD, PhD, Medical Director, Medpace Introduction The notable success
Targeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
An Interactive Guide to ALK+ Lymphoma. Our understanding of lung cancer has changed From one disease to many subtypes LCD
An Interactive Guide to ALK+ Anaplastic Lymphoma Kinase Non-Small Cell Lung (NSCLC) Our understanding of lung cancer has changed From one disease to many subtypes Click to get started Learning about Lung
Impact of Targeted/Immunotherapy on Gamma Knife Radiosurgery
Impact of Targeted/Immunotherapy on Gamma Knife Radiosurgery Veronica Chiang, MD Yale University Department of Neurosurgery IGKRF Scientific Session University of Pennsylvania, Philadelphia June 23-24,
Case Studies. Ravi Salgia, MD, PhD
Case Studies Ravi Salgia, MD, PhD Professor and Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Associate Director for Clinical Sciences Research City of Hope 04-21-2018 Objectives
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
Dr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
Analysis of Circulating Tumor DNA: the Next Paradigm Shift in Detection and Treatment of Lung Cancer
Accepted Manuscript Analysis of Circulating Tumor DNA: the Next Paradigm Shift in Detection and Treatment of Lung Cancer David S. Schrump, MD, MBA, Julie A. Hong, MS PII: S0022-5223(18)30295-2 DOI: 10.1016/j.jtcvs.2018.01.060
Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and the Lung Cancer Disease Site Group
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and
Original Contribution
Original Contribution CARE DELIVERY ReCAPs (Research Contributions Abbreviated for Print) provide a structured, one-page summary of each paper highlighting the main findings and significance of the work.
The identification of epidermal growth factor receptor
Original Article Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 2 Insertions Geoffrey R. Oxnard, MD,* Peter C. Lo,* Mizuki Nishino, MD, Suzanne E. Dahlberg, PhD, Neal
Targeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
Osimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell
Editorial Osimertinib as first-line treatment of EGFR mutant advanced nonsmall-cell lung cancer Chong-Kin Liam Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival of patients with advanced lung adenocarcinoma before and after approved use of gefitinib in China Yu-Tao Liu, Xue-Zhi Hao, Jun-Ling Li, Xing-Sheng
PIK3CA mutations are found in approximately 7% of
Original Article Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas Juliana Eng, MD,*
ORIGINAL ARTICLE. Oncology and Translational Medicine DOI /s Abstract
Oncology and Translational Medicine DOI 10.1007/s10330-018-0281-1 August 2018, Vol. 4, No. 4, P158 P162 ORIGINAL ARTICLE Treatment and survival status of patients with EGFR mutation-positive stage IV lung
Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis
Showa Univ J Med Sci 30 2, 309 315, June 2018 Original Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis Ryo MANABE 1, Koichi ANDO
Disclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis
JBUON 2017; 22(3): 586-591 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Program 7:15 7:40 Translocations as predictive biomarkers in lung cancer: Overview Mari Mino Kenudson, MD 7:40 8:05 Translocation
Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung
HeSMO 6(2) 2015 19 23 DOI: 10.1515/fco-2015-0009 Forum of Clinical Oncology Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung Hanan Ezzat Shafik 1 *,
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
ALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system
Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system The Harvard community has made this article openly available. Please share how this
Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer
Original Article Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer Tetsuya Mizuno 1, Takaaki Arimura 1, Hiroaki Kuroda 1, Noriaki Sakakura 1, Yasushi
Ceritinib (non-small cell lung cancer)
IQWiG Reports Commission No. A17-32 Ceritinib (non-small cell lung cancer) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment
Ludger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
Introduction ORIGINAL ARTICLE
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
Targeted Therapies in the Management of Non-Small Cell Lung Cancer. A Multi-Disciplinary Approach
Targeted Therapies in the Management of Non-Small Cell Lung Cancer A Multi-Disciplinary Approach Course Faculty Medical Oncologists: Dr. Barb Melosky British Columbia Cancer Agency, Vancouver, BC Dr. Jeff
FACTORS ASSOCIATED WITH NEVUS VOLATILITY IN EARLY ADOLESCENCE
FACTORS ASSOCIATED WITH NEVUS VOLATILITY IN EARLY ADOLESCENCE The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Oliveria,
Non-Small Cell Lung Cancer:
Non-Small Cell Lung Cancer: Where We Are Today Sila Shalhoub, PharmD PGY2 Oncology Pharmacy Resident Shalhoub.Sila@mayo.edu Pharmacy Grand Rounds September 26, 2017 2017 MFMER slide-1 Objectives Identify
Accepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference: